GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in
patients with brain metastases from non-small cell lung cancer (NSCLC).